+33 (0)1 70 96 00 00

The company
The Technology
Products
Indications
News
Contact

Search for:

Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission

Home
Corporate
Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission

ODD-EMA Télécharger

Biotechnology company that researches and develops innovative medicines

SItemap

Contact
home
Indications
Legal Notice
News
Products
The company
The Technology

Recent Posts

Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission

September 15, 2022

Who are we? Meet Audrey Thiebaut – R&D Project Manager

April 14, 2022

Contact

Caen (FR) / Liège (BR)
+33 (0)1 70 96 00 00

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication